Ori Biotech

From global pharma to emerging biotech, teams are already seeing measurable impact with IRO across biology, process control, and operational efficiency.

The page provides data on Ori’s and its partners’ advancements in cell and gene therapy manufacturing.

Introducing IRO. The new standard in CGT manufacturing technology.

Home » News » Digital Tech Vital for Innovation in Cell/Gene Therapy Manufacturing

Home » News & Insights » Industry News & Trends

Ori shares press releases, media coverage, and industry insights about cell and gene manufacturing.

Home » News » New digital manufacturing technology eases adoption barriers

Jason C. Foster discusses the importance of the work Ori is doing to address barriers to access for cell and gene therapies, highlighting the urgent need for innovation in the CGT manufacturing technology space

Ori has expanded its global expertise, personnel, and facilities for its CGT manufacturing platform.

Ori Biotech has created a platform technology which automates cell & gene therapy manufacturing and has the potential to help make these treatments affordable and available to patients at scale.

Ori Biotech seeks to grow its team to develop innovative solutions in cell and gene therapy.

Jian has over 25 years of leadership experience in the biopharma Technical Operations. She is currently President/COO of Metagenomi, a genetics medicines company. Previously, she headed Global Manufacturing and Supply Chain at Kite Pharma where she led Yescarta launch and manufacturing scale-out.

Jonathan is Partner at Delin Ventures where he is responsible for investments in early stage technology businesses and funds. He has led investments into Ori, Agile Analog, Fluidic Analytics, Turbine.ai and Import.io.

Ori Biotech aims to improve access to cell and gene therapy for patients with cancer and rare diseases.

Bruce developed the first FDA-approved CAR-T cell therapy as Professor of Cancer Gene Therapy at the University of Pennsylvania Perelman School of Medicine.

Ori collaborates with academic institutions and companies to advance new manufacturing approaches for personalized treatments.

IRO is built to meet the demands of CGT, unlike legacy tools.